New Delhi | 18th December 2025: Shardul Amarchand Mangaldas & Co. (SAM) advised Nephrocare Health Services Limited (“Nephroplus”) on its initial public offering aggregating to approximately US$ 95.99 million (₹ 8,710.48 million), comprising a fresh issue of ₹ 3,534.05 million and an offer for sale of ₹ 5,176.43 million.
SAM acted as legal counsel to Nephroplus on Indian law aspects of the transaction, advising on the drafting and regulatory compliance for the IPO, including coordination with multiple domestic and international stakeholders and supporting the company through the prospectus filing and listing process.
The SAM team was led by Prashant Gupta, National Practice Head — Capital Markets and Devi Prasad Patel, Partner; and assisted by Divya Dhawan, Associate; Satakshi N. Dixit, Associate; and Arjun Bhatia, Associate.